![]() ![]() ![]() (NASDAQ: SRNE, "Sorrento") released positive Phase 1b trial data ( NCT03542838) of resiniferatoxin (RTX) with completed Day 84 effectiveness data (end-point analysis) for all patients and completed six-month follow-ups in all doses for all patients enrolled, with no negative safety signal as of September 2020.ĭr. 28, 2020 (GLOBE NEWSWIRE) - Sorrento Therapeutics, Inc. Pain control in patients with advanced disease (Kellgren-Lawrence grade 3/4) show persistence of relief beyond 6 months and composite WOMAC A+C suggests that RTX could be a promising alternative for control of refractory pain in patients candidates for elective joint replacement.Durable signal at 12 weeks post-injection justifies initiation of Phase 2 (dose confirmation against active drug and saline control). Dose of 12.5ug selected as the likely optimal intra-articular therapeutic dose for future clinical trials.The study is scheduled to complete the last patient follow-up (1 year) in 1Q2021. ![]() No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months post-administration.Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |